Richard M. Bergenstal

发表

Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study

Michael A. Wood, John B. Welsh, George Dailey, 2011, Diabetes Care.

Staged diabetes management: a systematic evidence‐based approach to the prevention and treatment of diabetes and its co‐morbidities

Roger S. Mazze, Ellie S. Strock, Gregg D. Simonson, 2001 .

Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry

David M. Maahs, Saleh Adi, Irl B. Hirsch, 2014, Diabetes Care.

Sensor-augmented pump therapy for A1C reduction (STAR 3) study: Results from the 6-month continuation phase

Michael A. Wood, John B. Welsh, Stephen N. Davis, 2013 .

Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes

Roman Hovorka, Thomas R. Pieber, Hood Thabit, 2020, Diabetes Care.

Staged diabetes management : a systematic approach

Roger S. Mazze, Ellie S. Strock, Gregg D. Simonson, 2006 .

Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes

R. Bergenstal, Deborah M Mullen, Richard M. Bergenstal, 2017, Diabetes technology & therapeutics.

REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Well-Controlled Adults With Type 1 Diabetes

Rodica Pop-Busui, Michael R. Rickels, Elena Toschi, 2017 .

Threshold-based insulin-pump interruption for reduction of hypoglycemia

David C. Klonoff, John B. Welsh, Scott W. Lee, 2014 .

The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c

David Rodbard, Peiyao Cheng, R. Beck, 2019, Journal of diabetes science and technology.

Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group

G. Alexander Fleming, Reinhard W. Holl, Lutz Heinemann, 2015, Diabetologia.

Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes

Benyamin Grosman, Bruce A. Buckingham, Stacey M. Anderson, 2017, Diabetes technology & therapeutics.

Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk

Dejian Lai, Barry R. Davis, Kelley R. Branch, 2016, Diabetes Care.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

R. Bergenstal, P. Home, M. Riddle, 2015, Diabetes Care.